Atlas Trials

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Clinical trial NCT05740995 · RECRUITING

Trial details

NCT number
NCT05740995
Sponsor
Shanghai Zhongshan Hospital
Status
RECRUITING
Study type
OBSERVATIONAL
Esophageal Squamous Cell CarcinomaNeoadjuvant Chemoimmunotherapy
Start date
2020-12-01
Primary completion
2023-12-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.